Multidisciplinary Approaches to GVHD

EP: 1.Differentiating Acute and Chronic Graft-vs-Host Disease

EP: 2.Navigating Chronic GVHD: Phases of Pathophysiology and Best Practices in Patient Monitoring

EP: 3.Optimizing Chronic GVHD Therapy

EP: 4.Navigating Treatment Decisions in Chronic GVHD

EP: 5.Overview of Advanced Therapies in cGVHD

EP: 6.Overview of the ROCKstar Study

EP: 7.Considerations for Third-Line Treatment in Chronic GVHD

EP: 8.Clinical Scenario: Treatment Selection in the third line and beyond in cGVHD

EP: 9.Recent Updates: REACH3, ROCKstar, and RWD

EP: 10.AGAVE-201: Axatilimab for cGVHD

EP: 11.Emerging Trends in Chronic GVHD: Promising Clinical Trials and the Future Treatment Landscape

EP: 12.Clinical Impact of Patient-Reported Outcomes in cGVHD

Now Viewing

EP: 13.Multidisciplinary Approaches to GVHD

Video content above is prompted by the following:

Given that more and more nontransplant oncologists and other related HCPs (dermatologists, pulmonologists, ophthalmologists, infectious disease specialists, rheumatologists, etc) are seeing patients receiving treatment for cGVHD in their clinical practice, what practical advice do you have for them to manage cGVHD?